Abalos Therapeutics Appoints Thomas Bogenrieder as Chief Medical Officer

Rhea-AI Summary

Abalos Therapeutics has appointed Thomas Bogenrieder, MD, PhD, as its new Chief Medical Officer. Dr. Bogenrieder brings over 17 years of international experience in clinical development, particularly in cancer immunotherapies. His expertise will bolster Abalos' efforts in clinical and regulatory strategies for its arenavirus-based product candidates aimed at treating solid tumors. Previously, he served as Chief Medical Officer at Evaxion Biotech and has held senior roles at Boehringer Ingelheim and GlaxoSmithKline. This leadership change is expected to enhance Abalos' innovation in cancer treatment.

Positive

• Dr. Bogenrieder's extensive experience in clinical development may enhance the effectiveness of Abalos’ product candidates.
• The leadership change could strengthen regulatory interactions, crucial for advancing clinical operations.

Negative

• Potential concerns about continuity and experience gaps following the management transition.

DÜSSELDORF, Germany--(BUSINESS WIRE)-- Abalos Therapeutics announced today the appointment of Thomas Bogenrieder, MD, PhD, as Chief Medical Officer. Dr. Bogenrieder will contribute more than 17 years of international clinical development experience including successfully guiding cancer immunotherapies through the clinical evaluation process. His expertise in the clinical development of cancer virotherapies will further strengthen the company’s leadership position and guide the design and implementation of clinical and regulatory strategies for the company’s product candidates. Abalos has developed a platform of arenavirus-based variants that have optimized anti-tumoral properties to trigger a highly precise and directed immune response against primary tumors and their metastases.

“Thomas’ extensive experience in the clinical development of immuno-oncology drug candidates coupled with his track-record of successfully navigating interactions with regulatory bodies will be invaluable as we begin ramping up our medical and clinical operations,” said Marcus Kostka, CEO of Abalos. “I am excited to welcome him to the Abalos team and look forward to working with him as we build the clinical development plan for our first arenavirus-based immuno-virotherapeutics product candidate and advance it towards clinical evaluation in solid tumor indications.”

“Abalos has pioneered a unique approach that utilizes the arenavirus to achieve precise and directed immune responses to reach distant metastases and provide long-term disease control. I value the opportunity to join a great team focused on meeting the needs of cancer patients with a scientifically distinct approach that has the potential to change the treatment paradigm in solid tumors,” commented Thomas Bogenrieder, Chief Medical Officer of Abalos.

Prior to his role at Abalos, Dr. Bogenrieder served as Chief Clinical Officer for AMAL Therapeutics, where he oversaw the clinical development of cancer vaccine candidates in combination with an oncolytic virus. Before AMAL, he served as Chief Medical Officer at Evaxion Biotech, a public company creating AI-driven, neoepitope-targeting personalized cancer immunotherapies and vaccines against infectious diseases. Over the course of his career, Dr. Bogenrieder has held several leadership roles in oncology and medical affairs at Boehringer Ingelheim and GlaxoSmithKline. Dr. Bogenrieder holds an MD from the Albert-Ludwigs-University, Medical School in Freiburg and a PhD from the University of Utrecht and completed a postdoctoral fellowship at the Memorial Sloan-Kettering Cancer Center in New York City.

About Abalos

Abalos Therapeutics has harnessed the unique immune stimulation of the arenavirus to develop a novel anti-cancer approach that provides the full breadth of the immune system’s power specifically against cancer cells. Through viral replication within cancer cells, Abalos’ arenavirus-based drug candidates are designed to awake precise innate and adaptive immune responses and activate all relevant immune cell types against primary tumors and metastases. Led by experienced biotech entrepreneurs and immunology pioneers, Abalos’ goal is to achieve a quantum leap in immuno-oncology. For more information, please visit www.abalos-tx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221018005074/en/

Abalos Therapeutics GmbH

Marcus Kostka, PhD, CEO

Phone: +49 211 540104-01

Email: kostka@abalos-tx.com

Abalos media inquiries

Trophic Communications

Stephanie May / Marie-Theresa Weickert

Phone: +49 171 185 56 82

Email: abalos@trophic.eu

Source: Abalos Therapeutics

FAQ

Who has been appointed as the new Chief Medical Officer of Abalos Therapeutics?

Thomas Bogenrieder has been appointed as the new Chief Medical Officer of Abalos Therapeutics.

What experience does Thomas Bogenrieder bring to Abalos Therapeutics?

He brings over 17 years of international clinical development experience, particularly in cancer immunotherapy.

What is the focus of Abalos Therapeutics' product candidates?

Abalos Therapeutics focuses on arenavirus-based treatments for solid tumors, utilizing innovative immune responses.

What impact might Thomas Bogenrieder's leadership have on Abalos?

His leadership is expected to enhance clinical and regulatory strategies, potentially advancing product candidates towards evaluation.